Moreover, tirzepatide outperformed dulaglutide for weight loss in type 2 diabetes (Frias et al., 2018), although it is difficult to ascribe this to biased GLP‐1 receptor agonism due to the potential for GIPR‐induced appetite suppression (Adriaenssens et al., 2019) and the fact that the large molecular size of dulaglutide may limit access to appetite regulatory centres to a greater extent than with tirzepatide. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.